Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint

Stock Information for Resverlogix Corp.

Loading

Please wait while we load your information from QuoteMedia.